Stryker Corporation $SYK Shares Acquired by Integrity Alliance LLC.

Integrity Alliance LLC. grew its stake in Stryker Corporation (NYSE:SYK) by 1,105.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,717 shares of the medical technology company’s stock after purchasing an additional 11,662 shares during the quarter. Integrity Alliance LLC.’s holdings in Stryker were worth $4,734,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SYK. Continuum Advisory LLC grew its position in Stryker by 5.8% in the 1st quarter. Continuum Advisory LLC now owns 532 shares of the medical technology company’s stock valued at $198,000 after buying an additional 29 shares in the last quarter. Oakworth Capital Inc. lifted its stake in Stryker by 0.5% during the first quarter. Oakworth Capital Inc. now owns 6,133 shares of the medical technology company’s stock valued at $2,283,000 after buying an additional 29 shares in the last quarter. Strategy Asset Managers LLC lifted its position in shares of Stryker by 1.4% in the first quarter. Strategy Asset Managers LLC now owns 2,134 shares of the medical technology company’s stock worth $794,000 after purchasing an additional 29 shares in the last quarter. Tritonpoint Wealth LLC lifted its position in shares of Stryker by 0.7% in the first quarter. Tritonpoint Wealth LLC now owns 4,042 shares of the medical technology company’s stock worth $1,508,000 after purchasing an additional 30 shares in the last quarter. Finally, Monetary Management Group Inc. increased its holdings in Stryker by 0.4% in the first quarter. Monetary Management Group Inc. now owns 7,668 shares of the medical technology company’s stock worth $2,854,000 after buying an additional 30 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by corporate insiders.

Stryker Price Performance

Shares of SYK opened at $392.57 on Wednesday. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The company has a market capitalization of $150.08 billion, a price-to-earnings ratio of 52.00, a price-to-earnings-growth ratio of 2.86 and a beta of 0.93. The business has a 50-day moving average of $389.39 and a 200-day moving average of $379.67.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio is presently 44.50%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Citigroup reiterated a “buy” rating and set a $455.00 price target (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Truist Financial set a $415.00 price target on Stryker and gave the company a “hold” rating in a report on Monday, August 4th. BTIG Research restated a “buy” rating on shares of Stryker in a research report on Monday, July 14th. Evercore ISI upped their price target on Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Finally, Wells Fargo & Company upped their price objective on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Fourteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $431.42.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.